Analysts see room to run, but the stock's already priced in much of the optimism.
In the quiet arithmetic of markets, Goldman Sachs raised its price target on Vita Coco from $41 to $47, affirming a buy rating on a company that has grown from a niche coconut water brand into a mid-sized functional beverage enterprise worth $2.4 billion. The move joined a wave of analyst upgrades reflecting genuine earnings momentum — a 17% revenue surge and a quarterly beat — even as insiders quietly sold shares near the stock's yearly peak. It is the perennial tension of markets made visible: those closest to a company lightening their load while those observing from a distance grow more convinced of its promise.
- Goldman Sachs, Wells Fargo, and Morgan Stanley all raised price targets within days of each other, creating a rare convergence of institutional optimism around a single mid-cap beverage stock.
- Shares are trading near a 52-week high of $43.65 — nearly double their yearly floor — putting pressure on new buyers to trust that momentum can outlast a premium valuation of nearly 40 times earnings.
- A strong Q3 earnings beat and 17.1% year-over-year revenue growth gave analysts concrete footing for their bullishness, but a PEG ratio above 2 signals the market is already pricing in a great deal of future success.
- Institutional investors now control nearly 89% of the company's shares, with major asset managers dramatically expanding positions — yet insiders sold over $139 million worth of stock in the past 90 days, a quiet counterweight to the public optimism.
- The stock sits at a crossroads: analyst consensus points upward, but the gap between the $47 target and the $39.75 average across all analysts reveals that conviction is uneven and the ceiling is still being negotiated.
Goldman Sachs raised its price target on Vita Coco to $47 per share on Thursday, up from $41, while maintaining a buy rating on the coconut water maker. With shares trading around $42.52 at the time, the new target implied roughly 10.5% upside — a vote of confidence that the company still has room to climb.
The move was not isolated. Wells Fargo had already lifted its target to $47 just days earlier, pairing it with an overweight rating, and Morgan Stanley raised its objective from $38 to $41, though with more measured equal-weight enthusiasm. Piper Sandler had upgraded the stock to overweight in August. Not all voices were bullish — Needham initiated with a hold, and Wall Street Zen had downgraded in June — but the prevailing wind was clearly upward. Six analysts rated the stock a buy, four a hold, landing the consensus at moderate buy with an average target of $39.75.
The optimism had a foundation. In its most recent quarter, Vita Coco posted earnings of $0.38 per share, beating expectations of $0.36, on revenue of $168.76 million that also cleared forecasts. Revenue grew 17.1% year over year, and the company's net margin of 11.5% and return on equity near 25% pointed to a business running with real efficiency. Shares had nearly doubled from their 52-week low of $25.79, and both the 50-day and 200-day moving averages confirmed a sustained uptrend.
Institutional money had been flowing in decisively. Wellington Management more than doubled its position, Invesco nearly quintupled its stake, and institutional investors collectively owned 88.49% of the company. Yet insiders told a quieter story — the CFO and COO both sold shares in September, and executives collectively offloaded more than $139 million worth of stock over the prior 90 days, even as analysts grew more vocal in their support.
Beyond coconut water, Vita Coco sells coconut oil and milk, Runa energy drinks, Ever & Ever packaged water, and PWR LIFT protein drinks — a portfolio designed to capture the broader shift toward natural and functional beverages. Whether the company can sustain 17% revenue growth and justify a P/E of nearly 40 remains the question that will define the stock's next chapter.
Goldman Sachs lifted its price target on Vita Coco to $47 per share on Thursday, raising the bar from $41 and signaling confidence that the coconut water maker has room to run. At the time of the announcement, shares were trading around $42.52, meaning the new target implied roughly 10.5% upside from that level. The brokerage maintained a buy rating on the stock, joining a chorus of recent upgrades from other major firms.
The timing of Goldman's move reflected a broader shift in analyst sentiment around the company. Wells Fargo had already lifted its own target to $47 just days earlier, on September 25th, and paired it with an overweight rating. Morgan Stanley, in the same window, raised its price objective from $38 to $41, though it stopped short of enthusiasm, assigning an equal-weight rating instead. Piper Sandler had upgraded the stock from neutral to overweight in August, setting a $39 target. Not every voice was bullish—Needham & Company initiated coverage with a hold rating, and Wall Street Zen had downgraded from buy to hold back in June—but the weight of recent moves tilted decidedly upward. Across the analyst community, six firms rated the stock a buy while four called it a hold, leaving the consensus at moderate buy with an average price target of $39.75.
Vita Coco's recent financial performance gave analysts concrete reasons to turn more constructive. In its latest quarterly earnings, reported in late July, the company posted earnings per share of $0.38, beating consensus expectations of $0.36. Revenue came in at $168.76 million, also ahead of the $162.20 million analysts had forecast. The quarter showed real momentum: revenue climbed 17.1% compared to the same period a year earlier, when the company had earned $0.32 per share. The company's net margin sat at 11.5%, and return on equity reached nearly 25%, metrics that suggested operational efficiency and shareholder value creation. For the full year 2025, analysts on average expected the company to deliver $1.07 in earnings per share.
The stock itself had climbed steadily through the year. Its fifty-two week range ran from a low of $25.79 to a high of $43.65, meaning shares had nearly doubled from their floor. The fifty-day moving average stood at $37.07, while the two-hundred day average was $35.23, both suggesting an uptrend in place. With a market capitalization of $2.42 billion, Vita Coco was a mid-sized player, but its valuation had compressed into premium territory: the P/E ratio of 39.74 reflected investor expectations for continued growth, while the PEG ratio of 2.27 suggested the market was pricing in meaningful earnings expansion ahead.
Institutional money had been flowing in. In the first quarter alone, major asset managers made significant moves. Wellington Management Group more than doubled its position, acquiring an additional 258,521 shares to reach 511,462 shares total, worth roughly $15.7 million. Invesco nearly quintupled its stake, buying 78,229 additional shares to hold 97,862 shares valued at $3 million. Northern Trust boosted its holdings by 3.4%, and TT International Asset Management initiated a new position worth about $3 million. GAMMA Investing LLC made an outsized move, raising its position by more than 3,200%, acquiring 25,544 shares. Institutional investors now owned 88.49% of the company's stock, a sign of deep confidence from professional money managers.
Insider activity painted a more mixed picture. In mid-September, CFO Corey Baker sold 1,000 shares at $40 each, reducing his stake by 2.52% to 38,754 shares. Days later, COO Jonathan Burth sold 3,173 shares at $42.50 per share, trimming his position by 4%. Over the prior ninety days, insiders had collectively sold more than 3.4 million shares worth $139.5 million—a substantial amount that suggested some executives were taking chips off the table even as external analysts grew more bullish. Corporate insiders still owned 32.3% of the company, maintaining meaningful skin in the game.
Vita Coco itself manufactures and distributes coconut water and related beverages across the United States, Canada, Europe, the Middle East, Africa, and Asia Pacific. Beyond its flagship Vita Coco brand, the company sells coconut oil and milk, juice products, Runa plant-based energy drinks, Ever & Ever packaged water, and PWR LIFT protein-infused fitness drinks. The diversification into adjacent categories reflected an effort to capture more of the functional beverage market as consumer tastes shifted toward natural and plant-based options. Whether the company could sustain its 17% revenue growth rate and justify a 40-times earnings multiple remained the central question for investors watching the stock trade near its fifty-two week highs.
Notable Quotes
Goldman Sachs maintained a buy rating on the stock— Goldman Sachs Group
Consensus rating across analysts is moderate buy with average price target of $39.75— MarketBeat.com analyst consensus
The Hearth Conversation Another angle on the story
What made Goldman Sachs suddenly more confident about Vita Coco?
The earnings beat in July showed the company delivering real growth—17% revenue increase year-over-year, and they topped profit expectations. That kind of execution gives analysts permission to raise targets.
But the stock's already up a lot. Doesn't that make the $47 target less meaningful?
Fair point. The stock was already near $43 when Goldman made the call, so they're not predicting a dramatic move. But they're saying there's still room, and they're putting their name behind a buy rating, which matters to institutional investors.
I noticed insiders were selling heavily. Doesn't that worry you?
It does raise a question. When executives sell millions of dollars worth of stock, they're signaling something—maybe just diversifying their wealth, maybe something else. But they still own a third of the company, so they haven't abandoned ship.
What about that P/E ratio of nearly 40? That seems expensive.
It is. The market is betting Vita Coco can keep growing earnings faster than the typical company. If growth slows, that valuation compresses quickly. The company needs to keep delivering.
Are there any skeptics?
Yes. Needham initiated coverage with a hold, and Wall Street Zen downgraded to hold back in June. Not everyone is convinced the stock deserves to trade at these levels. The consensus is moderate buy, not a ringing endorsement.
So what's the real story here?
A beverage company that's executing well and growing in a market people care about—plant-based, functional drinks. Analysts see more runway. But the stock's already priced in a lot of that optimism, so the margin of safety is thinner than it looks.